U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709

Angiotensin III (Ang III) is a bioactive heptapeptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A. In peripheral Angiotensin systems, Angiotensin II is the main effector peptide in the systemic circulation, although exogenous Angiotensin III can be as potent as Angiotensin II in, for example, stimulating aldosterone secretion or inhibiting renin release. In the rat brain, Angiotensin III was found to be equipotent with Angiotensin II as a pressor agent or dipsogen and was bound as avidly to the nervous system as Angiotensin II. Angiotensin receptor subtype AT1 has the greater affinity towards Angiotensin II and is also responsive to Angiotensin III, while the AT2 receptor subtype appears to be more sensitive to Angiotensin III but less responsive to Angiotensin II. Angiotensin III enhances blood pressure, vasopressin release and thirst when it is centrally administrated. Angiotensin III infusion increases blood pressure in healthy volunteers and hypertensive patients as well as augments aldosterone release. Although Angiotensin III does not change renal function in humans, it induces natriuresis in AT, receptor-blocked rats likely by binding to AT2 receptors. In addition, in cultured renal cells, this peptide stimulates the expression of many growth factors, proinflammatory mediators, and extracellular matrix proteins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.57 nM [IC50]
1.74 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
The biochemistry of the renin-angiotensin system and its role in hypertension.
1976 May 31
[Diagnostic tests for endocrine hypertension].
1984 Jan
Bioactive angiotensin peptides.
1998 May
Patents

Patents

Sample Use Guides

Ang III (3.5, 7, and 14 nmol/kg per minute) was infused cumulatively into the renal interstitialspace of the left (experimental) kidney each rat after a 1-hour control infusion
Route of Administration: Other
Human prostate cancer cell (DU145 and LNCaP) were used for activity evaluation. LNCaP and DU145 cells were seeded onto 24-well plates at a density of 2–5x10^4 cells/well. Cells were treated with Ang-III at various concentrations as indicated in the figures for 5 days. Simultaneously, the cells were pretreated with olmesartan for 30 min, and cultured in phenol red-freeRPMI plus 0.1% BSA in the presence of Ang-III for 5 days. After incubation in 5% CO2 at 37C, cells were harvested with trypsin and cell numbers were determined with a cell counter on day 5.
Name Type Language
2-8-ANGIOTENSIN II, 5-L-ISOLEUCINE-, ACETATE
Preferred Name English
ANGIOTENSIN III ACETATE
Common Name English
ANGIOTENSIN III, 4-L-ISOLEUCINE-, MONOACETATE (SALT)
Common Name English
Code System Code Type Description
PUBCHEM
72941629
Created by admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
PRIMARY
CAS
1354552-78-5
Created by admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
NON-SPECIFIC STOICHIOMETRY
FDA UNII
2AY78S427U
Created by admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
PRIMARY
CAS
100900-06-9
Created by admin on Mon Mar 31 22:41:09 GMT 2025 , Edited by admin on Mon Mar 31 22:41:09 GMT 2025
PRIMARY